Respiratory Inhalation Devices Market Sales Analysis: 2023–2033

The global respiratory inhaler market is expected to grow significantly over the next decade. It is forecasted to grow from USD 37,258.5 million in 2023 to an impressive USD 60,114.7 million by 2033. This growth reflects a solid compound annual growth rate (CAGR) of 4.90% over the forecast period.

The increasing prevalence of respiratory diseases worldwide is a significant driver of this market expansion. As chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) continue to rise, the need for advanced and effective respiratory care solutions is intensifying. Inhalation devices, which are essential for managing and relieving symptoms, are therefore experiencing a concomitant growth.

“Inhalers are key to treating chronic respiratory diseases, and their evolving technology is key to improving patient outcomes,” says the FMI analyst. “R&D efforts focused on smart inhalers and new product innovations will drive growth in the market.”

Key Market Information:

Regional dominance: North America is expected to lead the market, with over 45 percent revenue share by the end of the forecast period.
Rapid growth in India: The Indian market is forecasted to witness the fastest annual growth rate at a CAGR of 6.10% during the forecast period.
Growth in China: In China, the respiratory inhaler market is expected to grow at a compound annual growth rate (CAGR) of 5.20%.
Product type: By 2033, metered dose inhalers are predicted to have a 75.4% market share.
Disease indication: By 2033, asthma is expected to dominate the market with a 66.8% share of revenue.

Get an instant business strategy Access the full report

Competitive Landscape:

The respiratory inhaler market is highly competitive and there are several key players who focus on innovation and product development. The major companies include AstraZeneca, Beximco Pharmaceuticals Ltd., Cipla Ltd., GlaxoSmithKline plc., OMRON Healthcare Europe BV, PARI Medical Holding, Teva Pharmaceutical Industries Ltd., Koninklijke Philips NV, Boehringer Ingelheim GmbH and Merck & Co., Inc.

Latest events:

In December 2020, OMRON Healthcare launched the WheezeScan device for pediatric asthma patients, which can accurately detect wheezing and reduce misdiagnosis.
In March 2021, AstraZeneca PLC initiated a Phase 3 clinical trial in the U.S. and Mexico to evaluate the safety and efficacy of budesonide/glycopyrronium/formoterol inhalers in adolescents and adults with persistent asthma. The study is expected to be completed in September 2023.
In May 2022, Alkem launched the “Innohaler”, the first inhalation device for asthma and COPD patients.

Market segmentation:

By product: Powder inhalers, metered dose inhalers, nebulizers (compressed air, ultrasonic, mesh)
By technology: Manually operated inhalation devices, digitally operated inhalation devices
According to disease indication: Asthma, chronic obstructive pulmonary disease, pulmonary arterial hypertension, other
By region: North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award winner and member of the Greater New York Chamber of Commerce) offers in-depth insights into the factors driving market demand. FMI is a leading global provider of market intelligence, advisory services, consulting and events for the packaging, food and beverage, consumer technology, healthcare, industrial and chemical markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional and local expertise on various industry disciplines and trends in over 110 countries.

Contact us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Apartment 401, Newark, Delaware – 19713, USA
Phone: +1-845-579-5705
For commercial inquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter| Blogs | YouTube